Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Talampanel · 5 trials · 7 indications
Change in frequency of recognizable seizures as measured by entries in a seizure diary
| Arm | Type | Description |
|---|---|---|
| Talampanel 50mg | EXPERIMENTAL | 50mg Talampanel 3 times per day |
| Talampanel 25mg | EXPERIMENTAL | 25mg Talampanel 3 times per day |
| Placebo | PLACEBO_COMPARATOR | placebo 3 times per day |
| enzyme-inducing antiseizure drug | EXPERIMENTAL | A single-arm study with all subjects assigned to one treatment (radiation + temozolomide + talampanel) but subjects receiving concomitant anti-seizure drugs which could increase study drug elimination had a slightly modified dose/schedule of study drug. The primary endpoint is analyzed as a single group. |
| 1 | PLACEBO_COMPARATOR | Enzyme-inducing placebo TID |
| 2 | EXPERIMENTAL | Enzyme-inducing Talampanel 35 mg TID |
| 3 | EXPERIMENTAL | Enzyme-inducing TLP 50mg TID |
| 4 | PLACEBO_COMPARATOR | Non-enzyme-inducing placebo TID |
| 5 | EXPERIMENTAL | Non-enzyme-inducing TLP 25mg TID |
| 6 | EXPERIMENTAL | Non-enzyme-inducing TLP 35mg TID |
| Talampanel | EXPERIMENTAL | - |
| Moxifloxacin | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Talampanel | DRUG | capsules Talampanel, 3 times per day, 52 weeks |
| placebo | OTHER | capsules, placebo, 3 times a day, for 52 weeks |
| Radiation Therapy (RT) 5 days a week + | RADIATION | - |
| temozolomide(TMZ) 75mg | DRUG | temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks |
| adjuvant TMZ 200mg | DRUG | adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months. |
| Moxifloxacin | DRUG | Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10 |
Subjects with sporadic or familial ALS classified as definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria. Inclusion Criteria: 1. Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria. 2. Subject has experienced his/her ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. | AMLX | 2 | PHASE3 | AMX0035 |
| Biogen Inc. | BIIB | 2 | PHASE3 | Tofersen |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | ION363 |
| Corcept Therapeutics Incorporated. | CORT | 1 | PHASE2 | Dazucorilant |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | VHB937 |
| argenx SE Sponsored ADR | ARGX | 1 | PHASE2 | ARGX-119 |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-166 |
| Coya Therapeutics, Inc. | COYA | 1 | PHASE2 | COYA 302 |
| Clene Inc | CLNN | 1 | PHASE2 | CNMAu8 |
| Eli Lilly and Company | LLY | 2 | PHASE1 | 89Zr-DFO-AP-101 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | ALN-SOD |
| Insmed Incorporated | INSM | 1 | PHASE1 | INS1202 |
| uniQure N.V. | QURE | 1 | PHASE1 | AMT-162 |
| AC Immune SA | ACIU | 1 | EARLY_PHASE1 | Undisclosed |
| Design Therapeutics, Inc. | DSGN | 1 | - | Undisclosed |
Talampanel is an investigational small molecule being studied in neurology for several conditions, including epilepsy, ALS, glioblastoma multiforme, dyskinesias, and Parkinson's disease. It has also been evaluated in healthy volunteers. Talampanel is not approved and remains in clinical development.
Talampanel is being developed by Teva Pharmaceutical Industries Limited, whose stock trades under the ticker TEVA. The company has conducted clinical trials of Talampanel across multiple neurological indications.
Talampanel has completed Phase 1 and Phase 2 clinical trials. It is an investigational drug that has not received FDA approval and is not yet available commercially. The most advanced studies completed were Phase 2 trials in glioblastoma multiforme and ALS.
Talampanel has been studied in several completed trials, including NCT00036296 in advanced Parkinson's disease, NCT00267592 in glioblastoma multiforme, NCT00696332 in ALS, and NCT00964730 in healthy volunteers. These trials were Phase 1 or Phase 2 and are all completed.
Talampanel is not known to have alternative names. It is a distinct investigational compound developed by Teva Pharmaceutical Industries. No other names for this drug have been reported.